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Introduction
Hair loss, known medically as alopecia, is a very common phe-
nomenon, affecting both males and females. Demographically, 
it effects about half of males and a quarter of females by the 
age of 50 (Vary , 2015) This makes it very likely we will be 
affected by hair loss during our lifetime. Hair loss can manifest 
itself in various forms, the most common being male pattern 
baldness defined as the progressive loss of hair beginning in 
some cases at puberty, and proceeding throughout adulthood 
(Berman, 2015). Another form of hair loss is alopecia areata, 
an autoimmune condition where the body mistakenly attacks 
healthy hair follicles. Alopecia areata effects men, women and 
children with hair loss occurring in the form of patches on the 
scalp, and in extreme forms, a complete loss of hair (subtype 
known as alopecia totalis) (Moskowitz , 2014). True, hair loss 
is not a disease in a sense that it effects our physical wellbeing, 
however, it is a condition which may cause severe psycho-
logical distress, particularly anxiety and depression upon the 
affected individuals (Hunt, McHale, 2005). These psychological 
effects, combined with the widespread prevalence of hair loss 
make it imperative for us to find a cure. In this paper, the pri-
mary focus will be on exploring whether or not hair loss can 
be prevented, and if hair lost hair can be regrown. Since hair 
loss due to hormonal causes is the most prevalent and studied 
form, it will be the focus of this paper.
Anatomy of the Hair Follicle
To get a better understanding of the mechanisms responsible 
for hair loss, it is vital we discuss how hair growth occurs in 
a healthy individual. In mammals, formation of the hair follicle 
takes place during fetal skin development. Cells which form 
the hair follicle, sebaceous and apocrine glands (responsible for 
producing oils and sweat) are all derived from ectodermal stem 
cells. In contrast, cells derived from mesodermal stem cells will 
develop into the follicular dermal papilla and the connective 
tissue sheath, while the neural crest derived melanocyte pro-
genitors produce the pigmentary cells, which are responsible 
for the coloring of hair (Fuchs, 2008). 
Although hair follicles vary in shape and size, they all have the 
same basic structure. The base of the follicle known as the papil-
la, is primarily composed of connective tissue and a capillary 
loop which supplies nutrients to the hair follicle. Cell division at 
the papilla is very rare (Pawilna, Ross , & Kaye, 2003). 
Superficial to the papilla, lies the hair matrix, the site of hair 
formation. In mammals the matrix contains trichocytes, the 
cells responsible for hair production. These epithelial cells 
produce modified keratin proteins, which contain ample 
amounts of the amino acid cysteine. Cysteine has a reactive 
sulfhydryl group which creates both inter and intra-chain 
linkage within a protein structure, thereby giving hair high 
tensile strength, and flexibility (Langbein & Schweizer, 2005). 
Also, contained within the matrix are scattered melanocytes. 
Just superficial to the matrix, lies the root sheath. The root 
sheath is further subdivided into the inner and outer root 
sheath. The inner sheath contains three different layers, a cu-
ticle layer, Huxley, and Henle’s layer. The outer layer contains 
the bulge, a stem cell rich area which supplies the entire 
follicle with new stem cells. These stem cells are vital in the 
healing process of an epidermal wound. Also, contained in 
the outer sheath is the sebaceous gland, responsible for hair 
lubrication. In the uppermost region of the outer sheath are 
the attachment sites of the arrector pili, smooth muscles that 
serve to help the hair maintain a vertical position (Ma & Yang, 
2004). The entire unit consisting of the hair, hair follicle, pili 
muscles and sebaceous gland is referred to as the piloseba-
ceous unit (PSU). 
Hair Growth Cycle
There are three phases of hair growth, the anagen, catagen, and 
telogen. The anagen phase is what is known as the growth phase. 
During this stage the cells in the root divide rapidly. After dividing, 
the cells produce a new hair that pushes the old hair out of the 
shaft. At this time, the hair grows approximately 1cm every 28 
days. The anagen phase is active for about 2-6 years.
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Individuals who have trouble growing their hair to a proper 
length might have a short anagen phase, whereby their hair falls 
out to a renewed anagen phase. In contrast, individuals who have 
the ability to grow their hair exceedingly long are likely have a 
growth phase lasting very long. It should be noted that auxiliary 
hair such as that of the eyebrows, eyelashes and arms have a very 
short growth phase, lasting 30-40 days. This is why we don’t have 
eyelashes that are more than a few millimeters in length.
The catagen phase is a transitional stage, which lasts from two 
to three weeks. At any given time about 3% of all hair are in this 
stage. During the catagen stage, hair growth stops, and the outer 
root sheath shrinks due to its detachment from the nutrient 
rich capillaries. At this point, a hard, club begins to form at the 
base of the hair, which is composed of hard keratinized tissue. 
This club holds the hair in place for as long as three months.
The telogen phase is the resting phase and usually last for about 
100 days on the scalp and longer for the hair of the eyebrow, 
eyelash, arm and leg. During this phase the hair follicle is com-
pletely inactive, and the club becomes more solidified. If one 
pulls out a hair at this stage, a hard, dry and solid root will be 
visible. In a normal individual, about 25-100 telogen hairs shed 
each day (Elzouki, et al. ,2012). People with androgenetic alo-
pecia don’t have regrowth occurring at the same rate. Typically, 
the hair loss begins above the temples and vertex of the scalp, 
and as it progresses, a rim of hair remains at the side and the 
back of the scalp.
Causes of Male Pattern Baldness
Androgens and their role in hair loss 
Androgens (the hormones responsible for the characteristic 
male appearance) play an important role in some, but not all 
hair growth. During puberty, the body produces significantly 
greater amounts of androgens to stimulate male development. 
One of the more noticeable effects androgens have is on the pi-
losebaceous units in the pubis, axilla (armpit), and lower face. In 
these regions, the hair goes from a fine, straight and almost col-
orless appearance, to a darker, thicker and curlier appearance. 
Additionally, in the areas of the upper face and trunk, the pilose-
baceous units respond to these same androgens, by drastically 
increasing the size of the sebaceous gland, thereby increasing 
the amounts of oils they produce (Alonso & Rosenfeld, 2003). 
In the male body, the major bioavailable form of androgens is 
testosterone. Testosterone can also be converted to a similar 
compound know as dihydrotestosterone (DHT) by the enzyme 
5α−reductase, which reduces the 4,5 double bond. DHT has a 
significantly greater binding affinity and lower dissociation con-
stant with the androgen receptor when compared to testoster-
one, hence DHT is a lot more potent. In men, approximately 5% 
of all testosterone molecules get converted by 5α−reductase 
into DHT (French, et al., 1990). 
The importance of DHT in males is clearly demonstrated in 
individuals who have a deficiency in the 5α−reductase. Such in-
dividuals display phenotypical pseudohermaphroditism, a condi-
tion where the male genitalia and prostate are underdeveloped, 
even though they have a genetic makeup of a male (Imperato-
McGinleyet al., 1979).
 The androgen receptor is a 110kD protein with a ligand bond-
ing domain, a DNA binding domain and two activation function 
regions that confer transcriptional regulatory activity. When a 
ligand binds to the androgen receptor in the cytoplasm, it ex-
poses the nuclear localization signal. This allows it to dimerize 
with another androgen receptor and then be transported to 
the nucleolus. In the nucleus, the androgen receptor complex 
binds to a specific region of DNA known as the hormone 
response element, where it either up-regulates or down-reg-
ulates translation of specific genes. The effects of mediation by 
the androgen receptor complex are highly variable (Alonso & 
Rosenfeld, 2003). 
It is widely believed that DHT is the major cause of baldness. 
Paradoxically, individuals with a genetic predisposition to baldness 
have an opposite response in some of their pilosebaceous units. 
In such individuals, the units in the scalp revert from being thick 
and darker in color, to being thin and lighter. However, the exact 
mechanism as to how DHT causes baldness remains to be deter-
mined. Furthermore, we have yet to understand why DHT acts in 
a paradoxical manner when affecting hair growth, creating baldness 
in some areas while stimulating new hair growth in other areas.
Although no definitive theories exist, Ustuner (2013) has pro-
posed that gravity might play a role in causing baldnesss. He seeks 
to explain the unique pattern of manifestation in effected individ-
uals by which is hair loss starts at the temples and the vertex of 
the scalp and proceeds to other areas. Ustuner believes that the 
weight of the facial tissue, which is supported by the scalp, causes 
damage to the hair follicles after puberty. During youth, there is 
sufficient fat tissue under the skin, which acts as a buffer to the 
hair follicles, and protects them from scalp pressure. However, 
this buffer gets diminished after puberty. The increase in DHT 
levels causes the fat layer to becomes increasingly thinner, essen-
tially losing its buffering ability. As a result, pressure in the hair 
follicles increases causing follicular damage, eventually leading to 
hair loss. He notes that women have a lower incidence of balding, 
due to the effect estrogen has on maintaining the subcutaneous 
fat, thereby preventing baldness until at least menopause (when 
estrogen levels decrease) (Ustuner, 2013). 
75
An Analysis on Whether or not Baldness can be Reversed
Ustuner continues to say that resulting increase in pressure 
weakens the follicle. To compensate for the increased pressure, 
the follicle sequesters more DHT more testosterone to make 
the hair follicle stronger.  As a result, the subcutaneous fat layer 
becomes even thinner, creating a vicious cycle. Ultimately, the 
hair follicle becomes smaller and smaller, resulting in greater 
amounts of hair loss. According to this theory, areas in the 
front of the scalp should have greater pressure, due to greater 
amounts of soft tissues (the face) pulling down the scalp. This 
is consistent with the actual pattern observed (Ustuner, 2013). 
One should be skeptical about this theory for several reasons. 
First, Ustuner does not explain the mechanism of how testos-
terone decreases the subcutaneous fat in the scalp.  Even though 
there is a correlation between an increase in testosterone and 
its derivatives and a decrease in subcutaneous scalp fat follow-
ing puberty, it is not proof of causation. Additionally, Ustuner 
does not address why or how testosterone causes an increase 
in hair growth in axillary areas (paradoxical effect of DHT).
Prostaglandin D2 and their suspected role in 
Hair Loss
Recently, there has been a new hypothesis as to what caus-
es baldness. Researchers have found that individuals with 
androgenetic alopecia have elevated levels of prostaglandin 
D2 (PGD2) in areas of the scalp that are balding, while not 
having elevated PGD2 levels in haired areas of the scalp in 
the same individual. They note that in normal individuals, 
PGD2 is elevated in the catagen (regression) phase. This 
alludes to PGD2 having an inhibitory effect on hair, as the 
catagen phase is the transitional stage where the hair begins 
the process of falling out (Garza, et al., 2012). Additionally, 
when researchers targeted prostaglandin synthase (enzyme 
responsible for prostaglandin synthesis) in transgenic mice, 
the mice displayed symptoms characteristic of androgenetic 
alopecia due the increased synthesis of PGD2.
Genetic Factors
Many different genes have been suspected to play a role in hair 
loss. Thus far, most genetic studies investigating genetic causes 
have implicated the androgen receptor (AR) gene. This gene lies 
on the X chromosome, and its biological identifier is Xq11-12 
(Ellis , et al., 2001). This is very intriguing, since as we have men-
tioned above, the most widely accepted cause of male pattern 
baldness is increased DHT levels. It would therefore be expect-
ed that the 5α−reductase gene be responsible for hair loss.
Treatments:
Finasteride (5α−reductase inhibitor)
In accordance with the theory that DHT is responsible for male 
pattern baldness, a 5α−reductase inhibitor should reduce male 
pattern baldness. Indeed, finasteride, a 5α−reductase inhibitor, has 
been one of only two FDA approved drugs used to treat hair loss. 
The recommended dosage for male pattern hair loss treatment is 
1 mg/day taken orally. During trials conducted to determine the 
efficacy of finasteride in treating male pattern baldness, a place-
bo controlled study was conducted with 42 healthy participants. 
The trial demonstrated that administration of finasteride from 
0.4 to 100 mg/day for up to 2 weeks significantly reduced the 
mean serum DHT from a baseline level. The reduction reached a 
maximum at the 1mg/day dosage. However, the study also found 
that 14 days after drug withdrawal, DHT returned to baseline 
levels. (Gormley, et al., 1990). In another study, individuals who 
were taking 1mg/day finasteride had a mean reduction in DHT of 
68.4% versus the placebo (Kaufman , et al., 1998). 
In the phase III placebo-controlled studies, the effects of finas-
teride on hair regrowth was assessed. Three studies were con-
ducted in this phase; all were randomized, double-blinded and 
placebo controlled, and included 1879 male patients ages 18-41 
years. All the individuals reported active shedding of hair at least 
3 years prior to volunteering for the study. Hair loss among sub-
jects ranged from mild to moderate. After categorically classify-
ing subject’s hair loss based on severity, they were given either a 
placebo or 1mg/day finasteride for 1 year. To detect whether or 
not finasteride increased hair growth, a baseline hair count was 
obtained before and after treatment, using macro-photographs 
of a 5.1cm2 area of the leading edge of the vertex with hair loss. 
After analyzing these photographs, finasteride was found to 
cause significant progressive increase in hair counts in all areas 
of the scalp studied (vertex, mid and frontal) during 12 months 
of treatment. There was an 11% increase in hair count in sub-
jects taking finasteride, compared to a 2.7% reduction in hair 
count during the same 12-month period in placebo subjects. 
Subjects taking finasteride for an additional year maintained 
their hair count, while those on the placebo continued to lose 
hair. After the 2-year period, 83% of those taking finasteride had 
no further hair loss, compared to only 28% of those taking the 
placebo. (Waldstreicher, et al., 1997). 
Overall, tolerability was the same for both the placebo and fi-
nasteride receiving groups. The only difference was in sexual 
function disorders which were reported in a higher percentage 
in the group receiving finasteride. It should be noted that al-
though there was a difference between both groups, the differ-
ence was relatively small, 3.8% in the placebo group and 2.1% 
in the group receiving finasteride. Additionally, of the subjects 
reporting sexual disorders during therapy, many cases were 
resolved even though they continued taking finasteride. All 
subjects who withdrew from the trial due to sexual disorders 
reported that the problems were resolved after discontinuing 
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the drug (Waldstreicher, et al., 1997). Based on these studies, it 
appears that finasteride does indeed reduce hair loss in most 
men. And since finasteride causes hair regrowth by altering 
DHT levels, it supports the DHT theory of baldness. 
More research has to be carried out to determine whether 
there is a link between male breast cancer and the use of fi-
nasteride, as has been suggested by the UK Medicines and 
Healthcare Products Regulatory Agency. They have suggested 
that male breast cancer might be linked to the decrease in the 
ratio of testosterone to estrogen when taking finasteride. For 
individuals using finasteride to treat hair loss, this suggestion 
should be taken with a bit of skepticism, as a majority of cases 
of male breast cancer was found in males taking the 5mg/day 
dose as a form of treatment for benign prostatic hyperplasia. In 
contrast, only a small percentage of prostate cancer was report-
ed in individuals taking the 1mg/day dose suggested for hair loss 
treatment (Shenoy & Prabhakar, 2010).  However, as one must 
continue using the drug to prevent further loss of hair, there is a 
need for long term studies of possible side effects.
It should also be noted that non-Caucasian participants ap-
peared to have less regrowth of hair compared to Caucasians. 
However, one has to be cautious in interpreting this, since only 
a small portion of the study subjects were non-Caucasian. To 
definitively state that non-Caucasians experienced less hair re-
growth, future studies conducted must include a representative 
number of non-Caucasian subjects.
Dutasteride
Similar to finasteride, dutasteride is also a 5α−reductase inhibitor, 
however, dutasteride inhibits not only type II, but also type I forms 
of 5α−reductase. Scientists don’t exactly know the effect type I 
5α−reductase inhibitor has on hair loss, since no deficiency has 
been found for it. However, evidence suggests that dutasteride is 
three times more potent than finasteride in inhibiting type II, and 
more than 100 times more potent in type I enzyme. (Clark , et al., 
2004). This would suggest that dutasteride would have a greater 
ability preventing hair loss, and promoting hair regrowth. Indeed, 
dutasteride has been found to decrease serum levels of DHT 
by more than 90% when compared to only 70% in finasteride. 
(Dallob, et al., 1994). 
In 2002, the FDA approved dutasteride as a treatment for benign 
prostatic hyperplasia. Phase trials were also conducted on its use 
as a treatment for male pattern baldness. During the phase II 
trails, researchers found increased hair growth on the scalp. They 
also found that a 2.5mg dosage of dutasteride was more effective 
than a 5mg dosage of finasteride (Olsen , et al., 2006). However, 
the phase III trials were put on hold due to concerns of side 
effects. For this reason, one should be hesitant in using this drug.
Minoxidil (Vasodilator)
Minoxidil, the second of only two drugs the FDA approved for 
treating hair loss, was initially developed as a treatment for ul-
cers. When minoxidil was applied to dogs during the trail phase, 
the ulcers did not improve, however, minoxidil was found to be 
a strong vasodilator. As a result, the FDA approved minoxidil 
tablets as a treatment for high blood pressure in 1979 (Conrad 
, 2008). Initially, when studies on the effectiveness of minoxidil 
as a vasodilator in humans were conducted, researchers found 
unexpected hair growth. That is when it occurred to research-
ers that minoxidil might be an effective treatment for hair loss 
(Gilmore, et al., 1970)
Although the mechanism of minoxidil’s ability to cause hair 
growth is poorly understood, some theories have been suggest-
ed. Minoxidil might increase hair growth by either shortening 
telogen or prolonging the anagen phase. Others propose that 
minoxidil is a potassium channel opener. When the potassium 
channel opens, it causes a hyperpolarization in cell membranes, 
this widens the blood vessels surrounding the hair follicle, 
thereby allowing more oxygen and nutrients into the follicle 
(Goren, et al., 2015). 
In the 1980s, studies reported that a 2% topical solution of mi-
noxidil reduced baldness in about 50% of patients. Although the 
study found that few mature terminal hairs were regrown, the 
number of fine, non-pigmented villus hairs were reduced. These 
studies acknowledged that the ideal candidates for minoxidil 
therapy were those who had been bald for less than five years, 
and whose baldness was less than 10cm in diameter and located 
on the vertex. They found that minoxidil was not useful for fron-
tal hair loss. Additionally, patients who discontinued treatment 
showed a rapid loss of the newly regrown hair. After 3 months 
of discontinuing therapy, their hair count was below baseline 
levels (Savin , 1987). 
After getting approved by the FDA as a treatment for hair loss 
in men, minoxidil became available under the name Rogaine, 
and was obtainable only by prescription. In 1996, Rogaine was 
approved for over-the-counter sale, and for the production of 
generic versions. Eventually a 5% topical solution was approved 
by the FDA (Conrad , 2008). 
Two studies have been conducted comparing the 2% versus the 
5% solution. One of the studies measured hair mass before and 
after a two-year period. This study found a greater hair mass in 
individuals taking the 5% solution. The difference was most ap-
parent early in the study. After taking the 5% solution for five 
months, these individuals experienced a 55% increase in total hair 
mass compared to the baseline, while those on the 2% solution 
only experienced a 25% increase. After the end of the 2-year 
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period, the 5% group had an increase of 25% over the baseline, 
while those on the 2% had only 15% (Price, 1996).  The second 
study found that the 5% minoxidil produced a significantly greater 
amount of non-villus hair by count as compared to the 2% group. 
They also found that patients using the higher dosage had an in-
creased likelihood of noticing more hair coverage on the scalp in 
their assessment of treatment benefits (Trancik, 1998). 
Generally, minoxidil is well tolerated, however, some side effects 
have been reported. The most frequent side effect is itching, red-
ness, or irritation of the scalp in the treated area. Unwanted hair 
growth elsewhere on the body has also been reported. Some indi-
viduals reported exacerbation of hair loss after applying minoxidil. 
Severe allergic reactions have also been reported including, rash, 
hives, difficulty breathing, tightness in the chest, swelling of the 
mouth, face, lips, or tongue, chest pain, dizziness, fainting, tachycar-
dia, headache, sudden and unexplained weight gain, and swelling of 
the hands and feet (Rogain Side Effects, 2015). Overall, it seems 
safe to say that minoxidil is a somewhat effective treatment for 
male pattern hair loss, however, compared to finasteride, it is less 
effective but has the advantage of being a topical. 
Ketoconazole (anti-fungal)
Ketoconazole, a common anti-fungal shampoo widely used in treat-
ing seborrheic dermatitis (dandruff), has also been suggested to 
contain hair regrowth properties. Recently, a study demonstrated 
that individuals applying a 2% solution of ketoconazole produced 
comparable levels of hair growth when compared to those using 2% 
minoxidil. Both groups achieved greater levels of hair growth com-
pared to those using un-medicated shampoo (Pierard-Franchimont, 
et al., 1998). Similar results were obtained when treating model 
mice with androgenetic alopecia with 2% ketoconazole, when com-
pared to the placebo group (Jiang, et al., 2005). 
Why ketoconazole causes hair regrowth is not clearly under-
stood. Some have suggested that ketoconazole plays a role in 
local disruption of the DHT pathway. They have suggested that 
when used in combination with finasteride, it may have a great-
er affect in reducing DHT levels compared to using finasteride 
on its own. (Perez, 2004). Its effect on DHT has been used to 
explain why some individuals using ketoconazole experience 
gynecomastia (enlargement of the breasts) (Wolverton , 2002). 
Clearly, it seems like ketoconazole has some hair regrowth abil-
ities, however, there is a need for more studies to be carried 
out to demonstrate how effective it is compared to placebo 
and other treatments. Additionally, more research needs to 
be done on the mechanism behind how it causes hair growth. 
Finally, studies have to demonstrate whether or not using keto-
conazole for an extended period of time is safe.
Low-level Light Therapy
Use of a ruby red laser (694nm) , resulted in increased hair 
growth in  mice who had their backs shaved (Mester, et al., 
1968). Although light therapy has been shown to effectively re-
duce inflammation, improve wound healing and reduce stroke 
symptoms, the mechanism behind it is poorly understood. Some 
have hypothesized that the light increases levels of ATP synthe-
sis in the mitochondria. There has been evidence that there is an 
increase in activity in complexes II and V in the electron trans-
port chain (Oron , et al., 2007). 
Many light therapies are marketed as treatments for hair loss. 
Typically, these devices are brushes or combs that have a red 
light shining out of the tips onto the scalp. Such devices are 
available for purchase over the counter. So far only one such 
device has been approved by the FDA as not being harmful, 
but does attest to its ability to treat hair loss. Such approval is 
sought after, as using certain wavelengths of light can be harmful. 
Companies have capitalized on the little research showing hair 
regrowth abilities and have produced light therapy devices for 
consumers, despite the little research that has been conducted 
to determine the safety and efficacy of it. As a consumer, one 
must therefore be very skeptical of buying such light therapy 
devices. More research must be done before anything definitive 
can be said about using light therapy to treat hair loss. 
Discussion
In light of research indicating that drugs can prevent further 
progression of hair loss, we may effectively conclude that hair 
loss can be treated. We cannot however conclude that hair loss 
can be cured, for a cure implies a reversal of a problematic med-
ical phenomenon. Hair loss as of yet cannot be cured because 
the effectiveness of hair loss drugs is only for as long as they 
are administered. To find a cure, a definitive theory explaining 
the causative mechanisms behind hair loss is necessary. Once 
we understand the mechanism behind hair loss, most certainly 
a cure will follow.
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